Q-omics provides the consensus-scored ZNF385A profile across patient tissues and cancer cell-line models. ZNF385A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF385A is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZNF385A RNA expression shows 17,872 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, HNSC, and BRCA as cancer lineages where ZNF385A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF385A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF385A survival associations across molecular data types. ZNF385A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF385A RNA expression–survival associations across cancer types. High ZNF385A expression shows unfavorable associations in KIRC, UVM, COAD, HNSC and LAML, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF385A RNA expression.
This table summarizes ZNF385A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF385A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF385A shows higher tumor expression in HNSC, KIRC, KIRP, LUSC, BRCA and LIHC. The HNSC box plot shows higher ZNF385A RNA expression in tumor versus normal tissue (log2 FC = +0.984, t-test p < 0.001).
This table shows molecular features associated with ZNF385A in patient tissues and cancer cell lines. In patient samples, ZNF385A shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF385A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
